Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer.
This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer.
2. Background of the EGFR receptor, biology of activation, regulation of EGFR in normal cells and cancer cells, mutations as oncogenic in NSCLC
3. Background of EGFR inhibitor development and implementation, assessment of how EGFR inhibitors have been implemented and are currently implemented
4. YAP signalling in EGFR inhibitor resistance
5. Apoptosis resistance in EGFR inhibitor resistance
6. EGFR mutations and resistance to EGFR inhibitors
7. SCLC transformation and resistance to EGFR inhibitors
8. EMT and resistance to EGFR inhibitors in EGFR mutant NSCLC
9. Intratumoral heterogeneity and resistance
10. Clinical trials of EGFR inhibitors in EGFR mutant lung cancer
11. Methodology of the detection of resistant mechanisms in the lung cancer clinic
